Format

Send to

Choose Destination
Oxid Med Cell Longev. 2014;2014:738679. doi: 10.1155/2014/738679. Epub 2014 Jun 29.

Approach to reduction of blood atherogenicity.

Author information

1
Institute for Atherosclerosis Research, Skolkovo Innovation Center, P.O. Box No. 21, Moscow 121609, Russia ; Institute of General Pathology and Pathophysiology, Baltiyskaya Street 8, Moscow 125315, Russia.
2
Institute for Atherosclerosis Research, Skolkovo Innovation Center, P.O. Box No. 21, Moscow 121609, Russia ; Institute of General Pathology and Pathophysiology, Baltiyskaya Street 8, Moscow 125315, Russia ; Russian Cardiology Research and Production Center, 3rd Cherepkovskaya Street 15a, Moscow 121552, Russia.

Abstract

We have earlier found that blood sera of patients with coronary heart disease (CHD) increase lipid levels in cells cultured from subendothelial intima of human aorta. We have also revealed that the ability of blood sera to raise intracellular cholesterol; that is, their atherogenicity is caused by at least modified low density lipoprotein (LDL) circulating in the blood of patients and autoantibodies to modified LDL. In the present work we have demonstrated significant impact of nonlipid factor(s) to blood atherogenicity. We have developed an approach to removal of nonlipid atherogenicity factor(s) from blood serum based on the use of immobilized LDL. This approach was used for extracorporeal perfusion of patient's blood through the column with immobilized LDL. Pilot clinical study confirmed the efficacy of this approach for prevention of coronary atherosclerosis progression.

PMID:
25101152
PMCID:
PMC4101215
DOI:
10.1155/2014/738679
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Hindawi Publishing Corporation Icon for PubMed Central
Loading ...
Support Center